Accordingly, we designed the ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary. The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce . statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound- Derived Coronary Atheroma Burden – ASTEROID. Mar 13, Share via: AddThis.

Author: Yozshull Kek
Country: Chad
Language: English (Spanish)
Genre: Politics
Published (Last): 26 May 2018
Pages: 486
PDF File Size: 11.72 Mb
ePub File Size: 13.39 Mb
ISBN: 229-8-90145-295-8
Downloads: 72000
Price: Free* [*Free Regsitration Required]
Uploader: Zolozuru

Treatment to LDL-C levels below currently accepted guidelines, yrial accompanied by significant HDL-C increases, can regress atherosclerosis in coronary disease patients. The number of clinical events in this month trial was too small for any meaningful analysis of the relationship between progression rate and morbidity or mortality. Nat Clin Pract Cardiovasc Med. However, exploratory analyses imputing less favorable IVUS outcomes for these patients did not alter the conclusions.

Further studies are needed to determine the effect of the observed changes on clinical outcome. In the current trial, each pair of baseline and follow-up IVUS images underwent digital processing to remove date identifiers, performed by technicians not otherwise involved in the study.

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. The baseline and follow-up pullbacks were reviewed as a pair.

Multiple muscle biopsies found no evidence of rhabdomyolysis. When feasible, clinical outcome trials rosuvadtatin assess the effects of therapies on morbidity and mortality always provide more convincing evidence than intermediate end-point studies.


The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

Sign in to customize your interests Sign in to your personal account. Effects of the acyl coenzyme A: Subsequently, every 60th image was analyzed, representing cross-sections spaced exactly 1. astdroid

asteroidd Most atherosclerosis trials have demonstrated that active lipid-modulating therapy, primarily using statin drugs, can reduce the rate of disease progression. The disposition of these patients is summarized in Figure 1.

The 22 patients who were withdrawn for ischemic events may represent progressors, a potential source of bias in the trial. The current study supports several conclusions.

After 24 months, patients had evaluable serial IVUS examinations.

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

Adverse events were infrequent and similar to other statin trials. Videotapes containing baseline and follow-up pullbacks were analyzed in the Intravascular Ultrasound Core Laboratory at the Cleveland Clinic Foundation.

The achieved LDL-C levels were the lowest values ever observed in a statin atherosclerosis progression trial, and the magnitude of the HDL-C increase also exceeded effects reported in previous statin trials. Regression of coronary atherosclerosis by simvastatin: A safety analysis was performed in all patients who received at least 1 dose of the study drug. Initial trials used quantitative coronary angiography or carotid ultrasound to determine the progression rates.

Moreover, arteries undergoing mechanical interventions were included, which could have affected atheroma measurements. A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months of treatment. The sponsor was permitted to review the manuscript and suggest changes, but the final decision on content was exclusively retained by the authors.


Patients were examined during scheduled clinic visits every 3 months.

Between November and Octoberpatients were screened and met all inclusion and exclusion criteria, including an acceptable baseline IVUS result, and received study drug at 53 centers. Of the 3 remaining deaths, 2 were due to sudden cardiac death and 1 to gastric carcinoma. Atherosclerosis is generally viewed as a chronic, progressive disease characterized by continuous accumulation of atheromatous plaque within the arterial wall.

The study sought to determine the effects of high-intensity lipid lowering on coronary disease progression. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men roosuvastatin high levels of apolipoprotein B.

Atheroma area was reduced from Table 4 shows the results for the primary end points for prespecified subgroups. Change in total atheroma volume showed a 6.

Get free access to newly published articles Create a personal account or sign in to: Unfortunately, the goal of inducing actual regression of atherosclerosis has remained elusive. The efficacy results are presented as mean and SD and median and interquartile range for the change from baseline. Nissen, MD ; Stephen J. Percent atheroma volume assesses drug effects within the full arterial pullback and represents the highest standard of evidence for regression.

The operator was instructed to select a starting point for interrogation as far distally as could be safely reached.